These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2996254)

  • 41. Administration of Protein Synthesis Inhibitor before Reminder Reverses Amnesia Induced by Memory Reconsolidation Impairment with 5-HT Receptors Antagonist.
    Nikitin VP; Kozyrev SA; Solntseva SV
    Bull Exp Biol Med; 2019 May; 167(1):1-6. PubMed ID: 31177445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats.
    DeNoble VJ; DeNoble KF; Spencer KR; Johnson LC; Cook L; Myers MJ; Scribner RM
    Pharmacol Biochem Behav; 1990 Aug; 36(4):957-61. PubMed ID: 2217526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypothermia-induced anterograde amnesia and its reversal in rats trained on a T-maze escape task.
    Santucci AC; Riccio DC
    Physiol Behav; 1986; 36(6):1065-9. PubMed ID: 3725911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose-response relationships in attenuation of puromycin-induced amnesia by neurohypophyseal peptides.
    Flexner JB; Flexner LB; Hoffman PL; Walter R
    Brain Res; 1977 Sep; 134(1):139-44. PubMed ID: 562219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vasopressin and physostigmine in the treatment of amnesia.
    Franceschi M; Tancredi O; Savio G; Smirne S
    Eur Neurol; 1982; 21(6):388-91. PubMed ID: 6756927
    [No Abstract]   [Full Text] [Related]  

  • 46. Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration.
    Brambilla F; Aguglia E; Massironi R; Maggioni M; Grillo W; Castiglioni R; Catalano M; Drago F
    Neuropsychobiology; 1986; 15(3-4):114-21. PubMed ID: 3097570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vasopressin in amnesia.
    Blake DR; Dodd MJ; Evans JG
    Lancet; 1978 Mar; 1(8064):608. PubMed ID: 76146
    [No Abstract]   [Full Text] [Related]  

  • 48. A treatment trial with an analog of thyrotropin-releasing hormone (DN-1417) in schizophrenia.
    Mizuki Y; Nishikori S; Kajimura N; Imaizumi J; Yamada M; Inanaga K
    Biol Psychiatry; 1985 Sep; 20(9):1030-5. PubMed ID: 2862926
    [No Abstract]   [Full Text] [Related]  

  • 49. Time-dependency of neurohypophyseal peptide attenuation of puromycin amnesia in mice.
    Walter R; Hoffman PL; Flexner JB; Flexner LB
    Int J Pept Protein Res; 1980 Nov; 16(5):482-6. PubMed ID: 7194322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Attenuation of experimentally-induced amnesia.
    Martinez JL; Jensen RA; McGaugh JL
    Prog Neurobiol; 1981; 16(2):155-86. PubMed ID: 6116260
    [No Abstract]   [Full Text] [Related]  

  • 51. [Montirelin hydrate (NS-3), a TRH analog, improved disturbance of consciousness in cats: electroencephalographical studies].
    Ukai Y; Ogasawara T; Yoshikuni Y; Kimura K
    Nihon Yakurigaku Zasshi; 1996 Jun; 107(6):273-84. PubMed ID: 8690308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological protection against hypoxia induced amnesia in rats.
    Giurgea C; Lefevre D; Lescrenier C; David-Remacle M
    Psychopharmacologia; 1971; 20(2):160-8. PubMed ID: 5104532
    [No Abstract]   [Full Text] [Related]  

  • 53. Transient hypoxic-amnesia: evidence for a triphasic memory-consolidating mechanism with parallel processing.
    Frieder B; Allweis C
    Behav Biol; 1978 Feb; 22(2):178-89. PubMed ID: 564688
    [No Abstract]   [Full Text] [Related]  

  • 54. Vasopressin in amnesia.
    Oliveros JC; Jandali MK; Timsit-Berthier M; Remy R; Benghezal A; Audibert A; Moeglen JM
    Lancet; 1978 Jan; 1(8054):42. PubMed ID: 74520
    [No Abstract]   [Full Text] [Related]  

  • 55. Amnestic disorders. Pathophysiology and patterns of memory dysfunction.
    Erickson KR
    West J Med; 1990 Feb; 152(2):159-66. PubMed ID: 2154898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose TRH treatment of neuromuscular diseases: summary of mechanisms and critique of clinical studies. Summary of section IX.
    Engel WK
    Ann N Y Acad Sci; 1989; 553():462-72. PubMed ID: 2497686
    [No Abstract]   [Full Text] [Related]  

  • 57. [Preparation of cerebral ischemia-induced amnesic model in mice and ameliorative effect of several compounds on the model].
    Kojima M; Kaneto H
    Nihon Yakurigaku Zasshi; 1989 Oct; 94(4):223-8. PubMed ID: 2613102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attenuation of cycloheximide-induced amnesia in mice with strychnine sulfate.
    Leccese AP; Quinton EE
    Behav Neurosci; 1983 Apr; 97(2):323-6. PubMed ID: 6682670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-amnesic effect of ACTH4-10: its independence of the nature of the amnesic agent and the behavioral test.
    Rigter H; Riezen HV
    Physiol Behav; 1975 May; 14(5):563-6. PubMed ID: 166400
    [No Abstract]   [Full Text] [Related]  

  • 60. Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
    Butler DE; Nordin IC; L'Italien YJ; Zweisler L; Poschel PH; Marriott JG
    J Med Chem; 1984 May; 27(5):684-91. PubMed ID: 6716406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.